180 related articles for article (PubMed ID: 23868668)
1. Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United States from 1999 to 2009.
Fisher BT; Singh S; Huang YS; Li Y; Gregory J; Walker D; Seif AE; Kavcic M; Aplenc R
Pediatr Blood Cancer; 2014 Jan; 61(1):68-73. PubMed ID: 23868668
[TBL] [Abstract][Full Text] [Related]
2. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
[TBL] [Abstract][Full Text] [Related]
3. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death.
Altman JK; Rademaker A; Cull E; Weitner BB; Ofran Y; Rosenblat TL; Haidau A; Park JH; Ram SL; Orsini JM; Sandhu S; Catchatourian R; Trifilio SM; Adel NG; Frankfurt O; Stein EM; Mallios G; Deblasio T; Jurcic JG; Nimer S; Peterson LC; Kwaan HC; Rowe JM; Douer D; Tallman MS
Leuk Res; 2013 Sep; 37(9):1004-9. PubMed ID: 23768930
[TBL] [Abstract][Full Text] [Related]
4. Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children.
Mann G; Reinhardt D; Ritter J; Hermann J; Schmitt K; Gadner H; Creutzig U
Ann Hematol; 2001 Jul; 80(7):417-22. PubMed ID: 11529468
[TBL] [Abstract][Full Text] [Related]
5. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan.
Ohno R; Ohnishi K; Takeshita A; Tanimoto M; Murakami H; Kanamaru A; Asou N; Kobayashi T; Kuriyama K; Ohmoto E
Leukemia; 1994; 8 Suppl 3():S64-9. PubMed ID: 7808028
[TBL] [Abstract][Full Text] [Related]
6. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group.
Kanamaru A; Takemoto Y; Tanimoto M; Murakami H; Asou N; Kobayashi T; Kuriyama K; Ohmoto E; Sakamaki H; Tsubaki K
Blood; 1995 Mar; 85(5):1202-6. PubMed ID: 7858250
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for early in-hospital death in patients who developed coagulopathy during induction therapy for acute promyelocytic leukemia: a nationwide analysis in Japan.
Matsuda K; Jo T; Toyama K; Nakazaki K; Matsui H; Fushimi K; Yasunaga H; Kurokawa M
Ann Hematol; 2021 Oct; 100(10):2613-2619. PubMed ID: 34308494
[TBL] [Abstract][Full Text] [Related]
8. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.
Tallman MS; Andersen JW; Schiffer CA; Appelbaum FR; Feusner JH; Woods WG; Ogden A; Weinstein H; Shepherd L; Willman C; Bloomfield CD; Rowe JM; Wiernik PH
Blood; 2002 Dec; 100(13):4298-302. PubMed ID: 12393590
[TBL] [Abstract][Full Text] [Related]
9. Childhood acute promyelocytic leukemia: no benefit of all-trans-retinoic acid administered in a short-course schedule.
Zubizarreta PA; Rose AB; Felice MS; Alfaro E; Delfino S; Cygler AM; Sackmann-Muriel F
Pediatr Hematol Oncol; 2000 Mar; 17(2):155-62. PubMed ID: 10734658
[TBL] [Abstract][Full Text] [Related]
10. Comparison of anthracycline-based combination chemotherapy with or without all-trans retinoic acid in acute promyelocytic leukemia.
Raza S; Ullah K; Ahmed P; Khan B
J Coll Physicians Surg Pak; 2008 Sep; 18(9):546-50. PubMed ID: 18803891
[TBL] [Abstract][Full Text] [Related]
11. All-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL).
Chim CS; Kwong YL; Liang R; Chu YC; Chan CH; Chan LC; Wong KF; Chan TK
Hematol Oncol; 1996 Sep; 14(3):147-54. PubMed ID: 9119359
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics and Treatment Outcomes of Childhood Acute Promyelocytic Leukemia in Korea: A Nationwide Multicenter Retrospective Study by Korean Pediatric Oncology Study Group.
Park KM; Yoo KH; Kim SK; Lee JW; Chung NG; Ju HY; Koo HH; Lyu CJ; Han SM; Han JW; Choi JY; Hong KT; Kang HJ; Shin HY; Im HJ; Koh KN; Kim H; Kook H; Baek HJ; Kim BR; Yang EJ; Lim JY; Park ES; Choi EJ; Park SK; Lee JM; Shim YJ; Kim JY; Park JK; Kong SG; Choi YB; Cho B; Lim YT
Cancer Res Treat; 2022 Jan; 54(1):269-276. PubMed ID: 33887821
[TBL] [Abstract][Full Text] [Related]
13. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
14. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
[TBL] [Abstract][Full Text] [Related]
15. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.
De Botton S; Dombret H; Sanz M; Miguel JS; Caillot D; Zittoun R; Gardembas M; Stamatoulas A; Condé E; Guerci A; Gardin C; Geiser K; Makhoul DC; Reman O; de la Serna J; Lefrere F; Chomienne C; Chastang C; Degos L; Fenaux P
Blood; 1998 Oct; 92(8):2712-8. PubMed ID: 9763554
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
17. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
18. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
[TBL] [Abstract][Full Text] [Related]
19. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome.
Tallman MS; Andersen JW; Schiffer CA; Appelbaum FR; Feusner JH; Ogden A; Shepherd L; Rowe JM; François C; Larson RS; Wiernik PH
Blood; 2000 Jan; 95(1):90-5. PubMed ID: 10607690
[TBL] [Abstract][Full Text] [Related]
20. [Treatment results of intermittent and cyclic regimen with ATRA and chemotherapy in childhood acute promyelocytic leukemia. Children's Cancer and Leukemia Study Group].
Hirota T; Fujimoto T; Katano N; Tsurasawa M; Eguchi H; Nakadate N; Kamitamari A; Kawakami K; Nishikawa K; Asami K; Shirahata A; Koizumi S; Mugishima H; Gushiken T; Hyakuna N; Imaizumi M; Komatu K; Takitani K; Miyake M; Yanase T
Rinsho Ketsueki; 1997 Nov; 38(11):1177-82. PubMed ID: 9423334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
